Medicamen Biotech Ltd vs Sms Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Medicamen Biotech Ltd is ₹ 253.3 as of 30 Apr 15:30 . The P/E Ratio of Medicamen Biotech Ltd changed from 53.8 on March 2021 to 86.2 on March 2025 . This represents a CAGR of 9.89% over 5 yearsThe P/E Ratio of SMS Pharmaceuticals Ltd changed from 16.8 on March 2021 to 27.3 on March 2025 . This represents a CAGR of 10.20% over 5 years The Market Cap of Medicamen Biotech Ltd changed from ₹ 652.37 crore on March 2021 to ₹ 612.46 crore on March 2025 . This represents a CAGR of -1.25% over 5 yearsThe Market Cap of SMS Pharmaceuticals Ltd changed from ₹ 1053 crore on March 2021 to ₹ 1885 crore on March 2025 . This represents a CAGR of 12.36% over 5 years The revenue of Medicamen Biotech Ltd for the Dec '25 is ₹ 47.44 crore as compare to the Sep '25 revenue of ₹ 47.54 crore. This represent the decline of -0.21% The revenue of SMS Pharmaceuticals Ltd for the Dec '25 is ₹ 214.2 crore as compare to the Sep '25 revenue of ₹ 243.86 crore. This represent the decline of -12.16% The ebitda of Medicamen Biotech Ltd for the Dec '25 is ₹ 4.91 crore as compare to the Sep '25 ebitda of ₹ 5.53 crore. This represent the decline of -11.21% The ebitda of SMS Pharmaceuticals Ltd for the Dec '25 is ₹ 47.4 crore as compare to the Sep '25 ebitda of ₹ 49.8 crore. This represent the decline of -4.82% The net profit of Medicamen Biotech Ltd changed from ₹ 0.8 crore to ₹ 1.63 crore over 7 quarters. This represents a CAGR of 50.19% The net profit of SMS Pharmaceuticals Ltd changed from ₹ 16.37 crore to ₹ 23.19 crore over 7 quarters. This represents a CAGR of 22.02% The Dividend Payout of Medicamen Biotech Ltd changed from 9.78 % on March 2021 to 13.45 % on March 2025 . This represents a CAGR of 6.58% over 5 yearsThe Dividend Payout of SMS Pharmaceuticals Ltd changed from 4.17 % on March 2021 to 5.19 % on March 2025 . This represents a CAGR of 4.47% over 5 years .

About Medicamen Biotech Ltd

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
The Company has presence over 35+ countries.
Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

About SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Limited was incorporated in December, 1987.
The company is engaged in the business of manufacturing of Active Pharma Ingredients and their intermediates.
Apart from R &D Center at Gagillapur, Hyderabad, the company is having manufacturing facilities at Bachupally, Hyderabad and also at Kandivalasa Village in Vijayanagaram District of Andhra Pradesh. During the year 2015, the company has re-enforced its fundamental strength of FDA compliant facilities by successfully completing the US FDA audits at Kandivalasa and Bachupally facilities. During the year 2015, the company filed 9 Drug Master Files and total DMFs filed up to 31 March 2015 are 24. During the year 2014-15, the Company acquired 12,25,900 equity shares of Rs. 10/- each in M/s.
VKT Pharma Private Limited.

FAQs for the comparison of Medicamen Biotech Ltd and SMS Pharmaceuticals Ltd

Which company has a larger market capitalization, Medicamen Biotech Ltd or SMS Pharmaceuticals Ltd?

Market cap of Medicamen Biotech Ltd is 343 Cr while Market cap of SMS Pharmaceuticals Ltd is 3,788 Cr

What are the key factors driving the stock performance of Medicamen Biotech Ltd and SMS Pharmaceuticals Ltd?

The stock performance of Medicamen Biotech Ltd and SMS Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Medicamen Biotech Ltd and SMS Pharmaceuticals Ltd?

As of May 3, 2026, the Medicamen Biotech Ltd stock price is INR ₹253.3. On the other hand, SMS Pharmaceuticals Ltd stock price is INR ₹404.55.

How do dividend payouts of Medicamen Biotech Ltd and SMS Pharmaceuticals Ltd compare?

To compare the dividend payouts of Medicamen Biotech Ltd and SMS Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.